Composition

Active substance:

1 capsule contains 150 mg sodium butyrate.

Excipients: fully hydrogenated palm oil, sodium alginate, mono and diglycerides of fatty acids, glycerol monolaurate.

Capsule: hydroxypropyl methylcellulose, titanium dioxide, purified water.

 

pharmacological properties

The main active ingredient of BUTIFAR drug is sodium butyrate, a natural short-chain fatty acid produced by the activity of microflora in the large intestine.

BUTIFAR is an anti-inflammatory, colonoprotective, regenerating, antisecretory, proapoptotic and prebiotic agent that ensures the normal functioning of the large intestine.

Sodium butyrate, a short-chain fatty acid, provides energy to large intestine cells (colonocytes), improves metabolism, causes normal development of colonocytes and increases the defense power against inflammatory-infectious diseases of the large intestine.

It reduces the activity of histone acetylase enzyme, inhibits the activity of nuclear factor NF-κB in colon cells and has an anti-inflammatory effect.

Butifar has an antisecretory effect, inhibits the transport of NaCl through the epithelial barrier and reduces the secretion of Cl- ions.

Butifar has a positive effect on the non-specific barrier properties of the intestinal wall. It restores the cells of the mucous membrane of the large intestine, improves the protective barrier, and has a regenerating effect. This is done by regulating the activity of transglutaminase, which is necessary for mucosal regeneration. MUC2, which is responsible for mucin production, stimulates mucin synthesis and mucus secretion by enhancing gene expression.

By inhibiting the cyclooxygenase-2 (SOG-2) enzyme, Butifar strengthens the proapoptotic effect of the body, prevents the formation and reproduction of tumor cells. It inhibits the pathological growth of colonocytes and protects against the damaging effects of carcinogens.

Butifar regulates the water-electrolyte balance in the intestine, has an anti-diarrheal effect, and ensures normal intestinal homeostasis.  

Butifar stimulates the production of antimicrobial peptides LL-37 and CAP-18 in colonocytes and phagocytes, which prevent the adhesion of bacteria to the mucous membrane of the gastrointestinal tract and prevent their invasion, and prevent the development of conditionally pathogenic bacteria. It restores the beneficial microflora by creating a normal environment in the large intestine. Butifar ensures normal nutrition of the mucous membrane of the large intestine, regulates its peristalsis (motor activity): it increases the level of immunoreactive neurons activated by the action of choline acetyltransferase, which causes disruption of the motor activity of the intestine, and decreases the level of neurons activated by the action of NO-synthetase. Also, it reduces the feeling of pain and regulates the act of defecation.

Butifar increases the endogenous synthesis of GLP1 or PYY in L-cells located in the large intestine, creates a feeling of satiety, reduces body weight, and prevents obesity. Increases mitochondria activity and energy consumption. 

It reduces the biosynthesis of cholesterol in the intestine.  

 

Instructions for use

BFMGA is recommended to improve the functioning of the large intestine in the following cases:

- Functional diseases of the colon (irritable bowel syndrome, functional diarrhea,

  functional constipation)

- Complex treatment of diarrhea of various origins 

- Inflammatory diseases of the colon (non-specific ulcerative colitis, Crohn's disease,

   microscopic  colitis).

- Colitis (infectious and non-infectious)

- Colonic diverticulum

- Disturbance of intestinal microflora of various origin (taking antibiotics, 

  intestinal infections, enterocolitis)

- Complex treatment of ischemic lesions of the colon

- Fatty infiltration of the liver (non-alcoholic, alcoholic) 

- Complex treatment of food allergy.

- Colon polyposis 

- Prevention of colorectal cancer 

- Complex treatment of obesity and hypercholesterolemia

- The period after chemotherapy and radiation therapy

- After large bowel surgery

 

Contraindications:

Hypersensitivity to any component of the preparation.

 

Method of use and dosage

Butifar capsules are taken orally with a glass (200 ml) of water during meals.

Use the following doses unless otherwise prescribed by a doctor.

Children and adults over 7 years old:

1 capsule 2 times a day (morning and evening).  

During chronic diseases of the colon, non-specific ulcerative colitis and Crohn's disease: 

2 capsules 2 times a day (morning and evening).

The minimum course of treatment is 3 months.

Dosage and administration can be adjusted by the doctor.

  

Release form

30 capsules, in blisters. 3 blisters (3x10) are packed in a cardboard box with an insert.

​

Producer:

Sensilab Ltd, Slovenia.